Distribution of neutralizing measles antibodies serum concentration according to age in women of childbearing age in France in 2005-2006

被引:3
作者
Gagneur, A. [1 ,9 ]
Pinquier, D. [3 ]
Aubert, M. [2 ]
Soubeyrand, B. [2 ]
Balu, L. [4 ]
Brissaud, O. [5 ]
Gras-Le-Guen, C. [6 ]
Hau-Rainsard, I. [7 ]
Mory, O. [8 ]
Picherot, G. [6 ]
De Pontual, L. [4 ]
Stephan, J-L. [8 ]
Reinert, P. [7 ]
机构
[1] CHU Brest, Dept Pediat, F-29609 Brest, France
[2] Sanofi Pasteur MSD, Lyon, France
[3] CHU Rouen, Dept Pediat, Rouen, France
[4] Hop Jean Verdier, Serv Pediat, Bondy, France
[5] Hop Pellegrin Enfants, Serv Neonatol, Bordeaux, France
[6] Hop Mere Enfant, CIC Pediat, Dept Pediat, Nantes, France
[7] CHI Creteil, Serv Urgences Pediat, Creteil, France
[8] CHU St Etienne, Hop Nord, Serv Pediat, St Etienne, France
[9] CHUS Sherbrooke, Dept Pediat, Sherbrooke, PQ, Canada
来源
ARCHIVES DE PEDIATRIE | 2008年 / 15卷 / 10期
关键词
D O I
10.1016/j.arcped.2008.07.011
中图分类号
R72 [儿科学];
学科分类号
100202 [儿科学];
摘要
Measles-vaccine coverage (MVC) increased significantly only beginning in 1983 based on the official recommendations. The majority of women born after 1983 should have vaccine-acquired rather than naturally derived immunity. Passively transferred measles antibodies (Mab) are expected to provide protection to offsprings during their 1st few months of life. Objective. Compare neutralizing Mab titers according to age in women aged 12-40 years, i.e., born before and after 1983. Methods. A multicenter seroepidemiological study was conducted in France in 2005-2006; 2.1.0 outpatient or hospitalized women were enrolled and classified into 4 age groups (12-18, 19-22, 23-30, and 31-40 years). Mab titers were assessed using a reference plaque reduction neutralization assay (protection threshold > 120 mIU/ml). Results. Ninety-four percent of subjects had a Mabs titer greater than 1.20 mlU/ml. Women born before 1983 had significantly higher geometric mean titers (GMTs) of Mabs than those born after 1,983 (1,358 mIU/ml vs. 731 mIU/ml [p < 0.001]). The comparison of the 4 cohorts showed a significant decrease) < 0.001) in GMTs of Mal) in the female population with increasing age (670, 771, 1173, and 1821 mUI/ml, respectively, in the 12-18, 19-22, 23-30, and 31-40 years age groups). For the 1st time in France, we show in women of childbearing age that in 2005-2006 neutralizing Mab GMTs were far above protective threshold for all age groups. Women in younger age groups (with high MVC) have significantly lower Mab titers. A lower passive transfer of Mab to their offsprings could result in a shorter period of measles protection and question the measles vaccine 1st dose at 1 year. (C) 2008 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:1525 / 1530
页数:6
相关论文
共 22 条
[1]
The modification in measles vaccination age as a consequence of the earlier decline of transplacentally transferred antimeasles antibodies in Turkish infants [J].
Altintas, DU ;
Evliyaoglu, N ;
Kilinc, B ;
SenAn, DI ;
Guneser, S .
EUROPEAN JOURNAL OF EPIDEMIOLOGY, 1996, 12 (06) :647-648
[2]
ANTONA D, 2003, B EPIDEMIOL HEBD, V36, P169
[3]
BONMARIN I, 2004, BEH, V16, P61
[4]
A study of maternally derived measles antibody in infants born to naturally infected and vaccinated women [J].
Brugha, R ;
Ramsay, M ;
Forsey, T ;
Brown, D .
EPIDEMIOLOGY AND INFECTION, 1996, 117 (03) :519-524
[5]
MEASLES VACCINATION OF INFANTS IN A WELL-VACCINATED POPULATION [J].
CARSON, MM ;
SPADY, DW ;
ALBRECHT, P ;
BEELER, JA ;
THIPPHAWONG, J ;
BARRETO, L ;
GRIMSRUD, KM ;
PABST, HF .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1995, 14 (01) :17-22
[6]
MEASLES ANTIBODY - REEVALUATION OF PROTECTIVE TITERS [J].
CHEN, RT ;
MARKOWITZ, LE ;
ALBRECHT, P ;
STEWART, JA ;
MOFENSON, LM ;
PREBLUD, SR ;
ORENSTEIN, WA .
JOURNAL OF INFECTIOUS DISEASES, 1990, 162 (05) :1036-1042
[7]
Transplacental transfer of measles and total IgG [J].
Gonçalves, G ;
Cutts, FT ;
Hills, M ;
Rebelo-Andrade, H ;
Trigo, FA ;
Barros, H .
EPIDEMIOLOGY AND INFECTION, 1999, 122 (02) :273-279
[8]
Immunity against measles in populations of women and infants in Poland [J].
Janaszek, W ;
Slusarczyk, J .
VACCINE, 2003, 21 (21-22) :2948-2953
[9]
LEUDIRAN E, 2007, VACCINE, V25, P6296
[10]
MALDONADO YA, 1995, PEDIATRICS, V96, P447